Mutations in the hemochromatosis gene and response to interferon in chronic hepatitis C

Sampietro, Maurizio; Corbetta, Noemi; Amato, Marcello; Casatta, A.; Lupica, L.; Mattioli, Massimo; Vitto, M. Del; Molteni, V.; Fiorelli, G.

doi:10.1016/s0168-8278(98)80769-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degre of hepatic inflammation and the serum HCV RNA titers did not differ between these groups. As for response to interferon, a recent study from Italy [23] found that 21% of 105 patients with chronic HCV infection and increased hepatic iron concentrations who did not respond to interferon treatment had the H63D mutation versus 10% of patients with normal hepatic iron content. The frequencies of the presence of the C282Y and the H63D mutations were 5% and 11%, respectively, in interferon responders versus 2% and 13%, respectively, in nonresponders.…”

Section: Iron Hfe Gene Testing and Chronic Viral Hepatitismentioning

confidence: 99%

Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis

Bonkovsky

Obando

1999

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Heavy iron overload, as occurs in primary and secondary hemochromatosis, may cause fibrosis of parenchymal organs, including the heart, liver, and pancreas, and it is a risk factor for the development of hepatocellular carcinoma. Recent evidence indicates that lesser degrees of hepatic iron deposition are also risk factors for nonhemochromatotic liver disease. For example, several recent studies showed extraordinarily high prevalences (about 60% to 75%) of HFE mutations in patients with porphyria cutanea tarda and significantly increased prevalences of these mutations in patients with nonalcoholic steatohepatitis from Australia and the United States. It is less well established that the prevalence of the HFE mutations is increased in alcoholic liver disease and in chronic viral hepatitis, but in both conditions, patients harboring one of these mutations, especially C282Y, are more likely to have advanced hepatic fibrosis or cirrhosis. Thus, these mutations both incite and exacerbate nonhemochromatotic liver disease. In this review, we summarize current knowledge of these associations and emphasize important unresolved questions that require further study.

show abstract

Section: Iron Hfe Gene Testing and Chronic Viral Hepatitismentioning

confidence: 99%